Cargando…
Availability of Essential Medicines for Pediatric Oncology in Armenia
BACKGROUND: One of the main contributors in low survival rate in LMIC is the lack of availability of cancer medications for curative, supportive and palliative care. In many developing countries access to cytotoxic medicine is a major challenge. The information about the availability of essential me...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
West Asia Organization for Cancer Prevention
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6948909/ https://www.ncbi.nlm.nih.gov/pubmed/31030465 http://dx.doi.org/10.31557/APJCP.2019.20.4.991 |
_version_ | 1783485823285460992 |
---|---|
author | Simonyan, Tamara Papyan, Ruzanna Danielyan, Samvel Sargsyan, Lilit Grigoryan, Varduhi Topchyan, Hakob Azaryan, Arpina Tananyan, Armen Muradyan, Armen Tamamyan, Gevorg |
author_facet | Simonyan, Tamara Papyan, Ruzanna Danielyan, Samvel Sargsyan, Lilit Grigoryan, Varduhi Topchyan, Hakob Azaryan, Arpina Tananyan, Armen Muradyan, Armen Tamamyan, Gevorg |
author_sort | Simonyan, Tamara |
collection | PubMed |
description | BACKGROUND: One of the main contributors in low survival rate in LMIC is the lack of availability of cancer medications for curative, supportive and palliative care. In many developing countries access to cytotoxic medicine is a major challenge. The information about the availability of essential medicines for pediatric cancer in the country is not known. The main objective of this study was to determine whether the medications used during the treatment of pediatric cancer are available in Armenia. METHODS: In summer 2016 we conducted a survey in the 3 main pharmacies in Yerevan, which import pediatric cancer medications to Armenia to evaluate whether medications used during cancer treatment are officially registered and available in the country. In addition, the information on official registration was cross-checked with the Ministry of Health of the Republic of Armenia (MOH). Simultaneously, detailed information about the drugs, on type of produced drug company, doses and price intervals was confined from the price lists of the national drug importer companies. RESULTS: The survey included 64 agents in three classes of medication: anti-neoplastics, anti-microbials, and drugs used in supportive care. All of these medications were included in the recent version of the WHO model list of essential medicines. From 30 anti-neoplastic medications on the essential medicines list 22 (73%) were officially registered in Armenia; from 19 anti-microbial drugs all were registered except caspofungin and from 15 supportive care agents 13 (87%) were registered. From registered anti-neoplastic drugs 18% and from antimicrobial drugs 33% were not available in the drug stores. CONCLUSION: This study showed that not all the drugs from the SIOP PODC Essential Medication list for pediatric oncology are officially registered and available in Armenia, and effective drug regulation focusing on the childhood cancer care medicine is needed for improving the situation in the country. |
format | Online Article Text |
id | pubmed-6948909 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | West Asia Organization for Cancer Prevention |
record_format | MEDLINE/PubMed |
spelling | pubmed-69489092020-02-04 Availability of Essential Medicines for Pediatric Oncology in Armenia Simonyan, Tamara Papyan, Ruzanna Danielyan, Samvel Sargsyan, Lilit Grigoryan, Varduhi Topchyan, Hakob Azaryan, Arpina Tananyan, Armen Muradyan, Armen Tamamyan, Gevorg Asian Pac J Cancer Prev Short Communication BACKGROUND: One of the main contributors in low survival rate in LMIC is the lack of availability of cancer medications for curative, supportive and palliative care. In many developing countries access to cytotoxic medicine is a major challenge. The information about the availability of essential medicines for pediatric cancer in the country is not known. The main objective of this study was to determine whether the medications used during the treatment of pediatric cancer are available in Armenia. METHODS: In summer 2016 we conducted a survey in the 3 main pharmacies in Yerevan, which import pediatric cancer medications to Armenia to evaluate whether medications used during cancer treatment are officially registered and available in the country. In addition, the information on official registration was cross-checked with the Ministry of Health of the Republic of Armenia (MOH). Simultaneously, detailed information about the drugs, on type of produced drug company, doses and price intervals was confined from the price lists of the national drug importer companies. RESULTS: The survey included 64 agents in three classes of medication: anti-neoplastics, anti-microbials, and drugs used in supportive care. All of these medications were included in the recent version of the WHO model list of essential medicines. From 30 anti-neoplastic medications on the essential medicines list 22 (73%) were officially registered in Armenia; from 19 anti-microbial drugs all were registered except caspofungin and from 15 supportive care agents 13 (87%) were registered. From registered anti-neoplastic drugs 18% and from antimicrobial drugs 33% were not available in the drug stores. CONCLUSION: This study showed that not all the drugs from the SIOP PODC Essential Medication list for pediatric oncology are officially registered and available in Armenia, and effective drug regulation focusing on the childhood cancer care medicine is needed for improving the situation in the country. West Asia Organization for Cancer Prevention 2019 /pmc/articles/PMC6948909/ /pubmed/31030465 http://dx.doi.org/10.31557/APJCP.2019.20.4.991 Text en This is an Open Access article distributed under the terms of the Creative Commons Attribution License, (http://creativecommons.org/licenses/by/3.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Short Communication Simonyan, Tamara Papyan, Ruzanna Danielyan, Samvel Sargsyan, Lilit Grigoryan, Varduhi Topchyan, Hakob Azaryan, Arpina Tananyan, Armen Muradyan, Armen Tamamyan, Gevorg Availability of Essential Medicines for Pediatric Oncology in Armenia |
title | Availability of Essential Medicines for Pediatric Oncology in Armenia |
title_full | Availability of Essential Medicines for Pediatric Oncology in Armenia |
title_fullStr | Availability of Essential Medicines for Pediatric Oncology in Armenia |
title_full_unstemmed | Availability of Essential Medicines for Pediatric Oncology in Armenia |
title_short | Availability of Essential Medicines for Pediatric Oncology in Armenia |
title_sort | availability of essential medicines for pediatric oncology in armenia |
topic | Short Communication |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6948909/ https://www.ncbi.nlm.nih.gov/pubmed/31030465 http://dx.doi.org/10.31557/APJCP.2019.20.4.991 |
work_keys_str_mv | AT simonyantamara availabilityofessentialmedicinesforpediatriconcologyinarmenia AT papyanruzanna availabilityofessentialmedicinesforpediatriconcologyinarmenia AT danielyansamvel availabilityofessentialmedicinesforpediatriconcologyinarmenia AT sargsyanlilit availabilityofessentialmedicinesforpediatriconcologyinarmenia AT grigoryanvarduhi availabilityofessentialmedicinesforpediatriconcologyinarmenia AT topchyanhakob availabilityofessentialmedicinesforpediatriconcologyinarmenia AT azaryanarpina availabilityofessentialmedicinesforpediatriconcologyinarmenia AT tananyanarmen availabilityofessentialmedicinesforpediatriconcologyinarmenia AT muradyanarmen availabilityofessentialmedicinesforpediatriconcologyinarmenia AT tamamyangevorg availabilityofessentialmedicinesforpediatriconcologyinarmenia |